Direct and indirect costs attributable to osteoarthritis in active subjects - PubMed (original) (raw)
Affiliations
- PMID: 16755664
Direct and indirect costs attributable to osteoarthritis in active subjects
Véronique Rabenda et al. J Rheumatol. 2006 Jun.
Abstract
Objective: To estimate the direct and indirect costs of osteoarthritis (OA) in an active population, and to identify factors significantly influencing these expenditures.
Methods: A cohort of 3,440 subjects employed by the Liège City Council was followed prospectively for 6 months. Subjects were asked to report monthly OA related health resource utilization (contacts with health professionals, medical examinations, drug consumption, etc.) and absence from work. Health related quality of life (HRQOL) was evaluated at baseline using the Medical Outcomes Study Short-form 36 (SF-36). Logistic regression analysis identified factors associated with the probability that the individual incurred costs, and multiple regression identified factors influencing the magnitude of these costs.
Results: A total of 1,811 subjects filled in at least one questionnaire (response rate 52%). The mean duration of followup was 3.46 months. Self-reported prevalence of OA was 34.1%. The mean total direct costs were 44.5 euros per OA patient-month. Contacts with health professionals, medical examinations, drugs, and hospital stays accounted for 23.7 euros, 8.7 euros, 6.7 euros, and 4.9 euros, respectively, per OA patient-month. The average number of sick-leave days was 0.8 per OA patient-month. From a payer's perspective, this loss of productivity represented a mean cost of 64.5 euros per OA patient-month. We also recorded 0.02 mean days off work per active subject-month due to informal care by relatives, yielding a mean cost of 1.8 euro per active subject-month for the employer. Poorer scores for most of the dimensions of the SF-36 at baseline were significantly associated with greater likelihood of incurring direct and indirect costs and with higher costs among subjects who reported costs. If we consider the overall cohort of active subjects, the burden of OA related to the direct and indirect costs was 15.2 euros and 23.8 euros, respectively, per active subject-month.
Conclusion: Direct and indirect costs attributable to OA are substantial, with productivity related costs being predominant. Poorer HRQOL was a major determinant of these expenditures.
Similar articles
- The direct and indirect costs of the chronic management of osteoporosis: a prospective follow-up of 3440 active subjects.
Rabenda V, Manette C, Lemmens R, Mariani AM, Struvay N, Reginster JY. Rabenda V, et al. Osteoporos Int. 2006;17(9):1346-52. doi: 10.1007/s00198-005-0066-x. Epub 2006 Jun 24. Osteoporos Int. 2006. PMID: 16799755 - The economic burden of disabling hip and knee osteoarthritis (OA) from the perspective of individuals living with this condition.
Gupta S, Hawker GA, Laporte A, Croxford R, Coyte PC. Gupta S, et al. Rheumatology (Oxford). 2005 Dec;44(12):1531-7. doi: 10.1093/rheumatology/kei049. Epub 2005 Aug 9. Rheumatology (Oxford). 2005. PMID: 16091394 - Economic burden of knee and hip osteoarthritis in Spain.
Loza E, Lopez-Gomez JM, Abasolo L, Maese J, Carmona L, Batlle-Gualda E; Artrocad Study Group. Loza E, et al. Arthritis Rheum. 2009 Feb 15;61(2):158-65. doi: 10.1002/art.24214. Arthritis Rheum. 2009. PMID: 19177521 - Economic costs of diabetes in the U.S. In 2007.
American Diabetes Association. American Diabetes Association. Diabetes Care. 2008 Mar;31(3):596-615. doi: 10.2337/dc08-9017. Diabetes Care. 2008. PMID: 18308683 Review. - The prevalence and burden of arthritis.
Reginster JY. Reginster JY. Rheumatology (Oxford). 2002 Apr;41 Supp 1:3-6. Rheumatology (Oxford). 2002. PMID: 12173279 Review.
Cited by
- Association between body roundness index and risk of osteoarthritis: a cross-sectional study.
Wang X, Guo Z, Wang M, Xiang C. Wang X, et al. Lipids Health Dis. 2024 Oct 14;23(1):334. doi: 10.1186/s12944-024-02324-5. Lipids Health Dis. 2024. PMID: 39402634 Free PMC article. - Work-related outcomes in individuals with and without lower limb osteoarthritis: an online survey.
Alyousef YS, Johnston V, Smith MD. Alyousef YS, et al. BMC Public Health. 2023 Sep 29;23(1):1885. doi: 10.1186/s12889-023-16723-3. BMC Public Health. 2023. PMID: 37773119 Free PMC article. - Sick Leave and Costs in Active Workers with Chronic Osteoarthritis Pain in Spain: Outcomes of the OPIOIDS Real World Study.
Sicras-Mainar A, Tornero-Tornero JC, Vargas-Negrín F, Lizarraga I, Sicras-Navarro A, Rejas-Gutierrez J. Sicras-Mainar A, et al. Open Access Rheumatol. 2022 Mar 15;14:25-38. doi: 10.2147/OARRR.S346746. eCollection 2022. Open Access Rheumatol. 2022. PMID: 35321217 Free PMC article. - Highly purified chondroitin sulfate: a literature review on clinical efficacy and pharmacoeconomic aspects in osteoarthritis treatment.
Reginster JY, Veronese N. Reginster JY, et al. Aging Clin Exp Res. 2021 Jan;33(1):37-47. doi: 10.1007/s40520-020-01643-8. Epub 2020 Jul 7. Aging Clin Exp Res. 2021. PMID: 32638342 Free PMC article. Review. - Impact of Mononuclear Cell Infiltration on Chondrodestructive MMP/ADAMTS Production in Osteoarthritic Knee Joints-An Ex Vivo Study.
Platzer H, Nees TA, Reiner T, Tripel E, Gantz S, Hagmann S, Moradi B, Rosshirt N. Platzer H, et al. J Clin Med. 2020 Apr 28;9(5):1279. doi: 10.3390/jcm9051279. J Clin Med. 2020. PMID: 32354196 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical